Glatiramer acetate
Pronunciation: Not available.
- Generic name
- glatiramer acetate
- Brand names
- Copaxone, Glatopa
- Drug class
- Immunomodulator
- Form
- Pre-filled syringe
- Route
- Subcutaneous injection
- Legal status
- Prescription-only medicine
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What glatiramer acetate is and how it works
Glatiramer acetate is a synthetic immunomodulator that is thought to lessen the immune system's abnormal attack on nerves in the brain and spinal cord. It is used to treat relapsing forms of multiple sclerosis in adults. (1)
It is given by subcutaneous injection using a pre-filled syringe. The first injection is administered under the supervision of a healthcare professional, and patients must be trained in proper injection technique and anaphylaxis recognition. Two different strengths with distinct dosing regimens exist; they are not interchangeable. Even after long-term use, life-threatening anaphylaxis can occur, so patients must be able to recognize the symptoms and seek immediate emergency care.
Mechanism of action: how glatiramer acetate works
Glatiramer acetate is a synthetic immunomodulator. Its mechanism in multiple sclerosis is not fully understood, but it is thought to lessen the immune system's abnormal attack on myelin in the central nervous system. (1)
What glatiramer acetate is used for
Relapsing forms of multiple sclerosis
Glatiramer acetate is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. (1)
Before taking glatiramer acetate
Do not take / not appropriate for
- Do not receive glatiramer acetate if you have a known hypersensitivity to glatiramer acetate or to mannitol (an ingredient in the injection). (all products) (1)
- Do not use glatiramer acetate if you have ever had an anaphylactic reaction to this medicine. (all products) (1)
Tell your clinician about
- Any previous hypersensitivity reaction to glatiramer acetate, mannitol, or any injection.
- History of liver disease, jaundice, unexplained fatigue, or abdominal pain.
- Pregnancy, plans for pregnancy, or breastfeeding.
- All other medicines you are taking, especially any other immunomodulating or immunosuppressive treatments.
- Your ability to recognize symptoms of anaphylaxis and to self-inject correctly.
How to take glatiramer acetate
- Glatiramer acetate is injected under the skin using a pre-filled syringe. The first injection must be given under the supervision of a qualified healthcare professional.
- Two dosing regimens are available and are not interchangeable: 20 mg/mL once daily, or 40 mg/mL three times per week (at least 48 hours apart). Use only the strength and schedule prescribed for you.
- Allow the pre-filled syringe to warm to room temperature before injecting.
- Do not change the dose, frequency, or strength without consulting the prescriber.
- You will receive training on proper injection technique and injection-site rotation. Follow the instructions exactly.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
Missed dose instructions are not available from the reviewed sources. Contact the prescribing clinician for guidance. Do not take an extra injection or change the schedule without advice.
Overdose
No specific overdose-management protocol was established from the sources reviewed for this draft; this remains an evidence gap. If an overdose is suspected, contact a poison control center or emergency services.
Side effects
Injection-site reactions are very common. Anaphylaxis is rare but can be life-threatening and can occur at any time, including after long-term treatment.
Injection-site reactions
What to notice: Redness, pain, itching, swelling, or a lump at the injection site. Lipoatrophy (permanent loss of fat tissue) may occur in about 2% of patients.
What to do: Rotate injection sites. Tell the clinician if reactions are severe, persistent, or if the skin appears sunken or damaged. (1)
Flushing, rash, and shortness of breath
What to notice: Feelings of warmth, skin rash, or difficulty breathing, sometimes occurring shortly after injection.
What to do: These are often transient. If they are severe or accompanied by other symptoms (e.g., throat tightness, wheezing, fast heartbeat), treat as a possible allergic reaction and seek emergency help. (1)
Transient chest pain
What to notice: Chest pain that usually begins at least one month after starting treatment, is temporary, and may be unrelated to the heart.
What to do: Inform the clinician if chest pain is severe, persistent, or accompanied by other concerning symptoms. (1)
Immediate post-injection reaction
What to notice: Within seconds to minutes of injection: flushing, chest pain, palpitations, rapid heartbeat, anxiety, difficulty breathing, throat constriction, or hives.
What to do: This reaction is usually transient and self-limiting, but it must be distinguished from anaphylaxis. Report the episode to your clinician promptly. (1)
Liver injury
What to notice: Jaundice (yellowing of the skin or eyes). A complete patient-facing symptom list was not established from the sources reviewed for this draft beyond this.
What to do: Seek medical attention promptly for anything that concerns you. The clinician will evaluate liver function and decide on treatment changes. (1)
Skin necrosis or severe local reaction
What to notice: Breakdown of the skin, open sores, or blackened tissue at the injection site.
What to do: Contact the clinician immediately for evaluation. The clinician will advise on whether, when, and where treatment can be administered. (1)
Serious warnings
Anaphylaxis — emergency
Symptoms: Wheezing, difficulty breathing, throat or tongue swelling, throat tightness, trouble swallowing, widespread hives, flushing, faintness, weak or rapid heartbeat, or a feeling of impending danger.
Action: Call emergency services immediately. Anaphylaxis can occur after any dose, even after years of treatment, and may be fatal. (1)
Severe hepatic injury — serious
Symptoms: Reported cases include liver failure and hepatitis with jaundice. A complete patient-facing symptom list was not established from the sources reviewed for this draft beyond this.
Action: Seek medical attention promptly for anything that concerns you. The clinician may check liver function and consider discontinuing the medicine. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Other immunomodulating or immunosuppressive therapies | The product label notes that glatiramer acetate can modify immune response. The reviewed source does not specify formal interaction studies or a list of contraindicated concurrent medicines — this is an evidence gap, not a confirmed absence of interactions. | Inform the prescriber of all medicines, especially those affecting the immune system. The clinical significance of concomitant use is uncertain. (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
Available data from pharmacovigilance and observational studies have not identified a drug-associated risk of major birth defects or miscarriage. Animal studies at doses much higher than the human dose did not show adverse effects on the fetus. Discuss the benefits and risks with your clinician. (1)
Breastfeeding
There are no data on the presence of glatiramer acetate in human milk. However, because systemic absorption after subcutaneous injection is very low, breastfeeding is not expected to result in clinically relevant exposure to the infant. Discuss with your clinician. (1)
Children and adolescents
Safety and efficacy in pediatric patients have not been established in the reviewed sources. No pediatric dosing or safety data are available.
Monitoring
Before starting
- Confirm the diagnosis of relapsing form of multiple sclerosis.
- Assess for any history of hypersensitivity to glatiramer acetate or mannitol.
- Review liver function and medical history, including current medications.
- Provide training on injection technique, injection-site rotation, and recognition of anaphylaxis.
- Administer the first injection under supervision of a healthcare professional.
During treatment
- Monitor for injection-site reactions, lipoatrophy, and skin necrosis; advise on proper rotation.
- Watch for signs of anaphylaxis at every injection, even after long-term use.
- Periodically evaluate liver function if symptoms of hepatic injury develop.
- In clinical studies, evaluations approximately every 3 months and MRI monitoring were used at specified intervals; this reflects study procedures observed in the reviewed source, not a universal monitoring guideline.
- Reassess the patient's ability to self-inject correctly and to recognize emergency symptoms.
Storage
Specific storage instructions were not established from the sources reviewed for this draft; this remains an evidence gap. Follow the product label and pharmacist instructions.
Professional information
Clinician-facing context only. Use the current local prescribing information and clinical guidelines.
United States
Indication: Relapsing forms of multiple sclerosis in adults
Dose summary: 20 mg/mL subcutaneously once daily, OR 40 mg/mL subcutaneously three times per week (at least 48 hours apart). These two regimens are not interchangeable. Renal and hepatic dose-adjustment information was not established from the sources reviewed for this draft.
Renal context: Renal dose-adjustment information was not established from the sources reviewed for this draft; this remains an evidence gap, not a reviewed-and-confirmed absence of adjustment. (1)
Hepatic guidance
Severe hepatic injury, including liver failure and hepatitis with jaundice, has been reported. Discontinuation should be considered by the treating clinician if signs of hepatic dysfunction emerge; specific monitoring intervals were not established from the sources reviewed for this draft.
Overdose note
No specific overdose-management protocol was established from the sources reviewed for this draft; this remains an evidence gap. (1)
Frequently asked questions
Can I switch between the 20 mg and 40 mg strengths of glatiramer acetate?
No. The two strengths are not interchangeable. The 20 mg/mL formulation is given once daily, while the 40 mg/mL formulation is given three times per week. Only use the strength and schedule prescribed by your clinician. (1)
How long does the immediate post-injection reaction last?
The reaction (flushing, chest pain, palpitations, anxiety, difficulty breathing, throat constriction, or hives) is usually transient and self-limiting. However, because it can resemble anaphylaxis, you should report it to your clinician. If symptoms are severe or you are unsure, seek emergency medical care. (1)
Can glatiramer acetate cause liver problems?
Yes, severe liver injury including liver failure and hepatitis with jaundice has been reported. Contact your clinician promptly if you notice jaundice (yellowing of the skin or eyes) or anything else that concerns you. (1)
What is the mechanism of action of glatiramer acetate?
Glatiramer acetate is a synthetic immunomodulator. Its mechanism in multiple sclerosis is not fully understood, but it is thought to lessen the immune system's abnormal attack on myelin in the central nervous system. (1)
What is the generic name of Glatiramer acetate?
The generic name is glatiramer acetate. It is sold under brand names including Copaxone, Glatopa. (1)
What class of drug is glatiramer acetate?
Glatiramer acetate is classed as: Immunomodulator. (1)
References
- COPAXONE- glatiramer acetate injection, solution full prescribing informationU.S. Food and Drug Administration · United States · dated unknown · accessed 2026-08-05 · source 1
- Glatiramer Injection — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 2
- Glatopa — FDA approval record (Drugs@FDA ANDA206921)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 3
- glatiramer — RxNorm normalized drug concept (RXCUI 214582)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 4
Brand names by country
Single-ingredient glatiramer acetate names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Glatopa20 mg/mL, 40 mg/mL · sandoz inc
- Copaxone20 mg/mL, 40 mg/mL · teva neuroscience, inc.
Canada
- COPAXONE